Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q2 2024 vs. Q1 2024
How the institutions holding Damora Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 26 | 22 | −4 |
| Shares | 3.96M | 4.04M | +80.9K (+2.0%) |
| Value | $3.09M | $1.91M | −$1.17M (−38.0%) |
New holders (4)
Institutions that held Damora Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 168,352 | $79.8K | 0.00% |
| Two Sigma Securities, LLC | 27,136 | $12.9K | 0.00% |
| Virtu Financial LLC | 14,678 | $7.00K | 0.00% |
| Group One Trading, L.P. | 68 | $32 | 0.00% |
Sold out (8)
Institutions that held Damora Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Bridgeway Capital Management, LLC | 73,100 | $57.0K |
| Jane Street Group, LLC | 26,213 | $20.4K |
| XTX Topco Ltd | 18,247 | $14.2K |
| Charles Schwab Investment Management Inc | 15,761 | $12.3K |
| Millennium Management LLC | 14,002 | $10.9K |
| ICA Group Wealth Management, LLC | 750 | $585 |
| Northwestern Mutual Wealth Management Co | 500 | $390 |
| Wells Fargo & Company | 155 | $121 |